Search results

1. Targeting enzymes of the parasite's purine salvage pathway as a new approach to combat H. pylori infections, including t…

Principal investigator: prof. Maria Agnieszka Bzowska

Uniwersytet Warszawski, Wydział Fizyki

Call: OPUS 26, Panel: NZ1

2. Reversible senescence as a new mechanism of cancer cell resistance for chemotherapy. Analysis of the mechanism of cancer…

Principal investigator: dr Karolina Anna Staniak

Politechnika Warszawska, Wydział Chemiczny

Call: SONATINA 5, Panel: NZ3

3. Regulation of epithelial to mesenchymal transition and therapy resistance to antitumor therapies by MCPIP1

Principal investigator: dr hab. Katarzyna Miękus

Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

Call: SONATA BIS 7, Panel: NZ5

4. The role of EZH2 activity in the development of resistance to targeted therapy in melanoma

Principal investigator: dr Michał Jerzy Woźniak

Uniwersytet Medyczny w Łodzi

Call: OPUS 28, Panel: NZ7

5. Precision double strike against non-small cell lung cancer. Insights into multidirectional therapies and the landscape o…

Principal investigator: dr Katarzyna Anna Malarz

Politechnika Śląska

Call: OPUS 27, Panel: NZ5

6. Cuproptosis, a novel pathway of regulated cell death as a therapeutic target in treatment-naïve and targeted therapy-res…

Principal investigator: dr hab. Mariusz Łukasz Hartman

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

Call: OPUS 25, Panel: NZ5

7. Unveiling the molecular signature underlying resistance to CD19 CAR-T therapy in malignant cells.

Principal investigator: Marta Krawczyk

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

Call: PRELUDIUM 22, Panel: NZ7

8. In search for molecular targets to overcome doxorubicin resistance in triple-negative breast cancer with the use of inno…

Principal investigator: Anna Karolina Pogorzelska

Narodowy Instytut Leków

Call: PRELUDIUM 20, Panel: NZ7

9. Cell adhesion molecules as regulators of tunneling nanotubes (TNTs) formation and protein transfer in leukemia microenvi…

Principal investigator: dr hab. Katarzyna Piwocka

Instytut Biologii Doświadczalnej im. M. Nenckiego PAN

Call: PRELUDIUM BIS 1, Panel: NZ3

10. Nanoencapsulated Photosensitizing Drugs for Photodynamic Therapy of Resistant Cancers and Microbes

Principal investigator: dr Janusz Marcin Dąbrowski

Uniwersytet Jagielloński, Wydział Chemii

Call: SONATA BIS 6, Panel: NZ7

11. RE-SENSE: Dual-loaded lipid nanoparticles to overcome the resistance of non-small cell lung cancer cells to personalized…

Principal investigator: Mikołaj Czajkowski

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Call: PRELUDIUM 20, Panel: NZ7

12. Mathematical modelling of drug resistance in anticancer therapies.

Principal investigator: dr Mariusz Piotr Bodzioch

Uniwersytet Warmińsko-Mazurski w Olsztynie, Wydział Matematyki i Informatyki

Call: PRELUDIUM 12, Panel: ST1

13. Immunomodulatory properties of nanosystems containing membrane-active compounds and their potential in therapy of drug r…

Principal investigator: Ewelina Piktel

Uniwersytet Medyczny w Białymstoku, Wydział Lekarski z Oddziałem Stomatologii i Oddziałem Nauczania w Języku Angielskim

Call: PRELUDIUM 10, Panel: NZ6

14. DNA repair pathways contributing to resistance to photodynamic therapy and as possible theraupeutic targets

Principal investigator: dr hab. Elżbieta Speina

Instytut Biochemii i Biofizyki PAN

Call: OPUS 8, Panel: NZ5

15. Inhibiting the Mitochondrial Intermembrane Space Assembly pathway as a newapproach to prevent metabolic reprogramming of…

Principal investigator: dr hab. Carlo Vascotto

Międzynarodowy Instytut Mechanizmów i Maszyn Molekularnych Polskiej Akademii Nauk

Call: OPUS 22, Panel: NZ5

16. FGF/FGFR-signalling in mediation of resistance to therapy in triple-positive breast cancer: clinical implications of PAM…

Principal investigator: dr hab. Hanna Maria Romańska-Knight

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

Call: OPUS 20, Panel: NZ4

17. The significance of cancer specific PFK-II (PFKFB3 and PFKFB4) isoenzymes inhibition in overcoming resistance to BRAF in…

Principal investigator: Sonia Elżbieta Trojan

Uniwersytet Jagielloński- Collegium Medicum, Collegium Medicum

Call: PRELUDIUM 16, Panel: NZ5

18. Role of RNA binding proteins in resistance to therapy of leukemia cells in bone marrow niche

Principal investigator: dr Paulina Podszywałow-Bartnicka

Instytut Biologii Doświadczalnej im. M. Nenckiego PAN

Call: HARMONIA 10, Panel: NZ3

19. Molecular and pharmacological approaches based on inhibition of glycolysis to overcome de novo- and antiangiogenic thera…

Principal investigator: dr hab. Beata Teresa Pająk

Wojskowy Instytut Higieny i Epidemiologii im. gen. Karola Kaczkowskiego

Call: OPUS 13, Panel: NZ3

20. Phosphorylation of translation initiation factor eIF2alpha as regulator of synthesis of proinflammatory and signaling cy…

Principal investigator: Wioleta Dudka-Ruszkowska

Instytut Biologii Doświadczalnej im. M. Nenckiego PAN

Call: PRELUDIUM 10, Panel: NZ3

21. The influence of bone marrow microenvironment on the regulation of BRCA1 mRNA translation in leukemia cells; role in the…

Principal investigator: dr Paulina Podszywałow-Bartnicka

Instytut Biologii Doświadczalnej im. M. Nenckiego PAN

Call: SONATA 8, Panel: NZ3

22. Immunological biomarkers of drug resistant epilepsy and response to immunomodulatory therapy with ACTH in children

Principal investigator: Magdalena Dorota Kaczorowska-Frontczak

INSTYTUT - POMNIK - CENTRUM ZDROWIA DZIECKA

Call: PRELUDIUM 6, Panel: NZ4

23. Photodynamic inactivation as a broad-spectrum antibiotic adjuvant reversing multidrug-resistant Gram-negative critical p…

Principal investigator: dr hab. Mariusz Stanisław Grinholc

Uniwersytet Gdański

Call: OPUS 29, Panel: NZ7

24. Light Against Darkness: Biocompatible Photoactivated Pharmaceuticals for Combating Multidrug Resistant Bacterial Infecti…

Principal investigator: dr hab. Janusz Marcin Dąbrowski

Uniwersytet Jagielloński

Call: OPUS 28, Panel: NZ7

25. Evaluation of the relationship between doxorubicin resistance, epithelial-mesenchymal plasticity, and effects of selecte…

Principal investigator: Dominika Kunachowicz

Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu, Wydział Farmaceutyczny z Oddziałem Analiutyki Medycznej

Call: PRELUDIUM 23, Panel: NZ5

26. Targeted poloxamer micelles with selected drugs as a strategy for overcoming the mechanisms of multidrug resistance in p…

Principal investigator: prof. Tomasz Adam Gośliński

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Call: PRELUDIUM BIS 4, Panel: NZ7

27. Design and implementation of effective cOmbination of Phages and Antibiotics for improved TheRApy protocols against KLEb…

Principal investigator: prof. Zuzanna - Drulis-Kawa

Uniwersytet Wrocławski, Wydział Nauk Biologicznych

Call: JPIAMR ACTION Call 2022, Panel: NZ6

28. The use of genetic analysis of liquid biopsy for predicting and monitoring ofresponse to therapies and tumor evolution i…

Principal investigator: dr Magdalena Olbryt

Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach

Call: OPUS 22, Panel: NZ7

29. Development of phage-based tool with the potential to treat antibiotic-resistant gonorrhea

Principal investigator: dr hab. Monika Julita Adamczyk-Popławska

Uniwersytet Warszawski, Wydział Biologii

Call: PRELUDIUM BIS 3, Panel: NZ6

30. The combination of radiotherapy with imiquimod and sunitinib as a new therapeutic strategy overcoming some of the tumor …

Principal investigator: dr Magdalena Jarosz-Biej

Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Oddział w Gliwicach

Call: SONATA 14, Panel: NZ5

31. Tunneling nanotubes (TNTs) within the leukemia microenvironment; influence of metabolic remodeling and implications for …

Principal investigator: dr hab. Katarzyna Piwocka

Instytut Biologii Doświadczalnej im. M. Nenckiego PAN

Call: OPUS 15, Panel: NZ3

32. Protein and gene expression analysis in the course of renal cancer stem-like cells' primary resistance to sorafenib in h…

Principal investigator: Zofia Felicja Bielecka

Wojskowy Instytut Medyczny

Call: PRELUDIUM 9, Panel: NZ5

33. Essential oils, propolis and nanoparticles of silver and copper as an alternative or supporting agent for conventional t…

Principal investigator: Katarzyna Magdalena Gucwa

Politechnika Gdańska, Wydział Chemiczny

Call: PRELUDIUM 8, Panel: NZ7

34. Role of the selected anti-tumor agents transported by electropermeabilization to the drug-sensitive and drug-resistant c…

Principal investigator: dr Joanna Barbara Weżgowiec

Politechnika Wrocławska, Wydział Podstawowych Problemów Techniki

Call: PRELUDIUM 8, Panel: NZ7

35. Identification and targeting molecular drug resistance mechanisms in adult B-cell acute lymphoblastic leukemia

Principal investigator: dr hab. Przemysław Juszczyński

Instytut Hematologii i Transfuzjologii

Call: OPUS 1, Panel: NZ4

36. New drug carriers in targeted anticancer therapy

Principal investigator: prof. Artur Piotr Terzyk

Uniwersytet Mikołaja Kopernika, Wydział Chemii

Call: OPUS 1, Panel: ST5

37. Phage-Antimicrobial combination Strategies for management of multidrug-resistant E. coli and K. pneumoniae

Principal investigator: prof. Krystyna Dąbrowska

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

Call: JPIAMR ACTION Call 2024, Panel: NZ7

38. "One step to game changer": combined antimicrobial therapy based on AI and nanotechnology to combat challenging diabetes…

Principal investigator: dr Barbara Ewa Pucelik

Sieć Badawcza ŁUKASIEWICZ - Krakowski Instytut Technologiczny

Call: SONATA 19, Panel: NZ7

39. Extensive analysis of the immunological profile of pediatric patients with acute lymphoblastic leukemia in order to iden…

Principal investigator: Anna Krętowska-Grunwald

Uniwersytet Medyczny w Białymstoku

Call: PRELUDIUM 22, Panel: NZ5

40. Dual CBR1-AKR1C3 inhibitors as a new approach to improve effectiveness and safety of anthracycline therapy.

Principal investigator: Marek Andrzej Jamrozik

Uniwersytet Jagielloński, Collegium Medicum

Call: PRELUDIUM 19, Panel: NZ7

41. The use of olaparib and ATR / CHK1 kinase inhibitors as a targeted anti-cancer therapy based on synthetic lethality

Principal investigator: dr hab. Aneta Katarzyna Rogalska

Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

Call: SONATA BIS 9, Panel: NZ7

42. Nano-phages - potential agents in an innovative therapy of bacterial infections

Principal investigator: dr Piotr Zdzisław Golec

Uniwersytet Warszawski, Wydział Biologii

Call: OPUS 12, Panel: NZ6

43. Role of Prolactin-Induced Protein (PIP) in breast cancer progression using an adjuvant therapy.

Principal investigator: prof. Piotr Zbigniew Dzięgiel

Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu, Wydział Farmaceutyczny z Oddziałem Analiutyki Medycznej, Wydział Lekarski

Call: OPUS 12, Panel: NZ5

44. Unlocking nature's potential - exploring the ability of newly isolated from the environment bacteriophage and its enzyme…

Principal investigator: Aleksandra Łukasiak

Uniwersytet Gdański, Wydział Biologii

Call: PRELUDIUM 22, Panel: NZ9

45. Three-phase drug carriers - design towards a prolonged release, development of a transport model and its verification. C…

Principal investigator: prof. Anna Trusek

Politechnika Wrocławska

Call: PRELUDIUM BIS 4, Panel: ST8

46. Fabrication of new photosensitive nanocomposites based on graphite oxide and their interaction with microorganisms which…

Principal investigator: dr Anna Łukowiak

Instytut Niskich Temperatur i Badań Strukturalnych im. Włodzimierza Trzebiatowskiego PAN

Call: OPUS 12, Panel: ST5

47. Old drugs - new perspectives: modulation of antibiotics activity by caffeine and pentoxifylline

Principal investigator: dr Anna Woziwodzka

Uniwersytet Gdański, Międzyuczelniany Wydział Biotechnologii Uniwersytetu Gdańskiego i Gdańskiego Uniwersytetu Medycznego

Call: SONATA 11, Panel: NZ7

48. Characterization and improvement of anti-cancer properties of second generation antagonists of Mdm2 oncoprotein

Principal investigator: dr Łukasz Skalniak

Uniwersytet Jagielloński, Wydział Chemii

Call: SONATA 11, Panel: NZ7

49. Identification of new, clinically relevant genetic and epigenetic aberrations by next-generation sequencing in chronic m…

Principal investigator: dr Tomasz Artur Stokłosa

Warszawski Uniwersytet Medyczny, Wydział Lekarski

Call: HARMONIA 6, Panel: NZ5

Projects search